Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorWermke, Martin
dc.contributor.authorFelip Font, Enriqueta
dc.contributor.authorGambardella, Valentina
dc.contributor.authorKuboki, Yasutoshi
dc.contributor.authorMorgensztern, Daniel
dc.contributor.authorHamed, Zohra Oum’
dc.date.accessioned2022-09-15T07:11:01Z
dc.date.available2022-09-15T07:11:01Z
dc.date.issued2022-08
dc.identifier.citationWermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed ZO, et al. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Futur Oncol. 2022 Aug;18(24):2639–49.
dc.identifier.issn1744-8301
dc.identifier.urihttp://hdl.handle.net/11351/8197
dc.descriptionT-cell engager; Eeuroendocrine carcinoma; Small-cell lung cancer
dc.description.abstractPoorly differentiated neuroendocrine carcinomas such as small-cell lung cancer (SCLC) have poor survival and high relapse rates. DLL3 is found on these carcinomas and has become a target of increasing interest in recent years. The bispecific DLL3/CD3 T-cell engager BI 764532 has been shown to induce complete tumor regression in a human T cell-engrafted mouse model. Here, we describe the study design of a first-in-human, phase I, multicenter, open-label, non-randomized, dose-escalation study in patients with SCLC or other DLL3-positive neuroendocrine carcinomas. The study will determine the maximum tolerated dose and evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of BI 764532 monotherapy.
dc.language.isoeng
dc.publisherFuture Medicine
dc.relation.ispartofseriesFuture Oncology;18(24)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPulmons - Càncer - Tractament
dc.subjectTumors neuroendocrins - Tractament
dc.subjectAnticossos monoclonals - Ús terapèutic
dc.subject.meshSmall Cell Lung Carcinoma
dc.subject.meshCarcinoma, Neuroendocrine
dc.subject.meshAntibodies, Bispecific
dc.subject.mesh/therapeutic use
dc.titlePhase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2217/fon-2022-0196
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decscarcinoma neuroendocrino
dc.subject.decsanticuerpos biespecíficos
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttps://doi.org/10.2217/fon-2022-0196
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Wermke M] Technical University Dresden, Medical Faculty, NCT/UCC Early Clinical Trial Unit, Dresden, Germany. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Gambardella V] Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. [Kuboki Y] Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. [Morgensztern D] Washington University School of Medicine, St. Louis, MO 63110, USA. [Hamed ZO] Boehringer Ingelheim France S.A.S., Reims, France
dc.identifier.pmid35815644
dc.identifier.wos000822742900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record